Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.43 |
| ▸ | CA2 | P00918 | 12/20 | 0.43 |
| ▸ | CA9 | Q16790 | 12/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA7 | P43166 | 11/20 | 0.43 |
| ▸ | CA4 | P22748 | 6/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | AOC2 | O75106 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060893 | 0.85 | CA1 (0.42) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16093348 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12CA7 | |
| SCHEMBL19683202 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21156445 | 0.84 | LMNA (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL13527224 | 0.83 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL20082505 | 0.81 | F2 (0.44) | PTGS2LOXL2F2 | |
| SCHEMBL13526959 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16788802 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9969521 | 0.81 | CYP2D6 (0.39) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17277443 | 0.79 | PTGDR2 (0.41) | PTGS2LOXL2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CA1 3502/4885CA2 3747/4885CA9 3961/4885 |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CA1 3502/4885CA2 3747/4885CA9 3961/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | CA1 1794/4885CA2 2606/4885CA9 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.